#SFHS2610748AFrance Adds Meropenem Kalceks to Hospital Reimbursement List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
France adds Meropenem Kalceks 1 g injectable powder to the list of medicines that hospitals can bill separately from standard hospital care payments. The reimbursement applies only for specific serious bacterial infections, including severe pneumonia, complicated urinary tract infections, complicated intra-abdominal infections, acute bacterial meningitis, and related bloodstream infections. Hospitals, hospital pharmacies, clinicians, and the manufacturer Ever Pharma France are directly affected. Care teams should use the medicine within the listed indications and follow official guidance on appropriate antibacterial use.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds Meropenem Kalceks 1 g injectable/perfusion powder to the hospital add-on reimbursement list
- Limits reimbursement to specified serious bacterial infections and related suspected or confirmed bloodstream infections
- Reminds healthcare providers to follow official guidance on appropriate antibacterial use
Obligations
What this law requires
Hospitals may bill Meropenem Kalceks 1 g powder for injectable/infusion solution separately from standard hospitalisation payments only when used within the therapeutic indications listed in the annex to Article L. 162-23-6 reimbursement list.
Hospital care teams must limit separately reimbursed use of Meropenem Kalceks 1 g to adults and children aged 3 months or older treated for the specified infections, including severe pneumonia, cystic fibrosis bronchopulmonary infections, complicated urinary tract infections, complicated intra-abdominal infections, intra- and post-partum infections, complicated skin and soft tissue infections, acute bacterial meningitis, febrile neutropenia with suspected bacterial origin, or associated/suspected bacteraemia linked to those infections.
Clinicians and hospital antimicrobial stewardship teams must take account of official recommendations on appropriate use of antibacterial medicines when using Meropenem Kalceks 1 g under the reimbursed indications.
The listed reimbursable product must be identified as Meropenem Kalceks 1 g powder for injectable/infusion solution, UCD code 3400890033466, exploited or marketed by Ever Pharma France, when applying separate hospital reimbursement.